Neurocrine Biosciences vs United Therapeutics
Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $15.2B
- Last close
- $150.57
- 12 months
- +8.3%
- Market value
- $23.6B
- Last close
- $554.73
- 12 months
- +16.9%
At a glance
- The biggest part of United Therapeutics's revenue is Tyvaso DPI, 41% of the total in its last annual report.
- By market value, United Therapeutics ($23.6B) is about 1.6 times Neurocrine Biosciences ($15.2B).
- Over the last 12 months Neurocrine Biosciences's share price moved +8.3% and United Therapeutics's +16.9%; against the S&P 500 that is +2.6 points and +11.1 points.
- In their last fiscal years Neurocrine Biosciences kept 16.7% of revenue as net income and United Therapeutics 41.9%.
- In the last 90 days insiders reported 0 open-market purchases at Neurocrine Biosciences and 0 at United Therapeutics; members of Congress disclosed 0 trades in Neurocrine Biosciences and 0 in United Therapeutics.
- Next results: Neurocrine Biosciences Feb 9, 2027, United Therapeutics Feb 23, 2027.
How each one makes money: Neurocrine Biosciences revenue · United Therapeutics revenue
Share prices on one chart
Neurocrine Biosciences and United Therapeutics, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Neurocrine Biosciences NBIXNASDAQ · Biotechnology | United Therapeutics UTHRNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $15.2B | $23.6B |
| Revenue, last fiscal year | $2.86B | $3.18B |
| Net income, last fiscal year | $479M | $1.33B |
| Net marginNet income as a share of revenue | 16.7% | 41.9% |
| Free cash flow | $749M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Common questions
How is Neurocrine Biosciences different from United Therapeutics?
Neurocrine Biosciences (NBIX) is in Biotechnology on NASDAQ, with $2.86B of revenue in its last fiscal year and a net margin of 16.7%. United Therapeutics (UTHR) is in Biotechnology on NASDAQ, with $3.18B of revenue in its last fiscal year and a net margin of 41.9%. The biggest part of United Therapeutics's revenue is Tyvaso DPI, 41% of the total in its last annual report. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Neurocrine Biosciences and United Therapeutics compare in size?
United Therapeutics has the larger market value: Neurocrine Biosciences $15.2B and United Therapeutics $23.6B, at the last close.
Whose share price rose more over the last 12 months, NBIX or UTHR?
Over the last 12 months Neurocrine Biosciences moved +8.3% and United Therapeutics +16.9%. Past price moves say nothing about the future.
Which has had more insider buying, Neurocrine Biosciences or United Therapeutics?
Since 2006, Neurocrine Biosciences insiders reported 106 open-market purchases against 43 for United Therapeutics. These are counts of what was filed, not a view on either stock.
Do members of Congress trade NBIX or UTHR?
In the last 12 months, members of Congress disclosed 0 trades in Neurocrine Biosciences (NBIX) and 0 in United Therapeutics (UTHR).
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Neurocrine Biosciences pageUnited Therapeutics pageRare insider trades this weekAll comparisons
https://oqro.io/compare/nbix-vs-uthr

